Manchester Science Partnerships

Bruntwood SciTech — a 50:50 joint venture between property developer Bruntwood and insurer Legal & General — holds the majority stake and sets strategic direction. The University of Manchester owns 12.2%, while Manchester Metropolitan University, Manchester City Council, and Manchester University NHS Foundation Trust hold minority positions (per Altss research). This governance structure means MSP answers to both a commercial property mandate and a regional innovation brief.

MSP generates revenue from laboratory and office rents across eight science park properties, then channels a portion of returns into direct venture investing. The GM&C Life Sciences Fund — managed from Alderley Park — makes equity investments in life sciences startups, many of which are MSP tenants. This landlord-as-LP model means the firm's real estate and venture portfolios share a single pipeline: the translational research coming out of its university and NHS partners.

Alderley Park is a 400-acre campus in Cheshire that MSP operates, formerly AstraZeneca's UK R&D headquarters. It now houses over 200 companies spanning biotech, agritech, and industrial life sciences, with shared equipment facilities, the Glasshouse collaborative workspace, and the GM&C Life Sciences Fund. The campus gives MSP a pharmaceutical-scale asset that its urban Manchester parks cannot replicate, effectively making it a national rather than strictly regional player.

MSP does both. Through the GM&C Life Sciences Fund, it takes equity stakes in early-stage therapeutics, diagnostics, and medtech companies. It also runs Mi-IDEA, a post-accelerator programme in partnership with Cisco, which prepares deep-tech companies for venture fundraising. These direct investment activities sit alongside its core property business of leasing lab and office space to science and technology tenants.

MSP concentrates on life sciences, digital health, diagnostics, precision medicine, enterprise software, and clean growth technologies. It does not invest in speculative real estate development, consumer internet, or financial services companies. The portfolio remains tethered to the translational strengths of its university and NHS shareholders — a deliberate constraint that focuses deployment on medically and industrially adjacent ventures.

Bruntwood SciTech, the majority owner of MSP, is a joint venture formed in 2018 between Bruntwood (a Manchester-based property company) and Legal & General Capital (the insurer's direct investment arm). Legal & General provides patient institutional capital through this structure, which allowed MSP to scale beyond its original university-park footprint and take on assets like Alderley Park and the Citylabs campus expansion.

MSP itself does not operate a charitable foundation, but its shareholder Manchester University NHS Foundation Trust maintains MFT Charity, which funds research, equipment, and patient support across the Trust's hospitals. MSP's Citylabs campus — built on MFT land — demonstrates the operational overlap: commercial lab tenancies directly fund NHS capital projects at the adjacent Manchester Royal Infirmary.